These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 25033084)

  • 1. An attenuated herpes simplex virus type 1 (HSV1) encoding the HIV-1 Tat protein protects mice from a deadly mucosal HSV1 challenge.
    Sicurella M; Nicoli F; Gallerani E; Volpi I; Berto E; Finessi V; Destro F; Manservigi R; Cafaro A; Ensoli B; Caputo A; Gavioli R; Marconi PC
    PLoS One; 2014; 9(7):e100844. PubMed ID: 25033084
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Systemic immunodominant CD8 responses with an effector-like phenotype are induced by intravaginal immunization with attenuated HSV vectors expressing HIV Tat and mediate protection against HSV infection.
    Nicoli F; Gallerani E; Skarlis C; Sicurella M; Cafaro A; Ensoli B; Caputo A; Marconi PC; Gavioli R
    Vaccine; 2016 Apr; 34(19):2216-24. PubMed ID: 27002499
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Herpes Simplex Virus 1 (HSV-1) 0ΔNLS Live-Attenuated Vaccine Protects against Ocular HSV-1 Infection in the Absence of Neutralizing Antibody in HSV-1 gB T Cell Receptor-Specific Transgenic Mice.
    Gmyrek GB; Filiberti A; Montgomery M; Chitrakar A; Royer DJ; Carr DJJ
    J Virol; 2020 Nov; 94(24):. PubMed ID: 32999018
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recombinant herpes simplex virus type 1 (HSV-1) codelivering interleukin-12p35 as a molecular adjuvant enhances the protective immune response against ocular HSV-1 challenge.
    Osorio Y; Ghiasi H
    J Virol; 2005 Mar; 79(6):3297-308. PubMed ID: 15731224
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The HIV-1 Tat protein induces the activation of CD8+ T cells and affects in vivo the magnitude and kinetics of antiviral responses.
    Nicoli F; Finessi V; Sicurella M; Rizzotto L; Gallerani E; Destro F; Cafaro A; Marconi P; Caputo A; Ensoli B; Gavioli R
    PLoS One; 2013; 8(11):e77746. PubMed ID: 24223723
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prophylactic Herpes Simplex Virus 2 (HSV-2) Vaccines Adjuvanted with Stable Emulsion and Toll-Like Receptor 9 Agonist Induce a Robust HSV-2-Specific Cell-Mediated Immune Response, Protect against Symptomatic Disease, and Reduce the Latent Viral Reservoir.
    Hensel MT; Marshall JD; Dorwart MR; Heeke DS; Rao E; Tummala P; Yu L; Cohen GH; Eisenberg RJ; Sloan DD
    J Virol; 2017 May; 91(9):. PubMed ID: 28228587
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapeutic immunization with a mixture of herpes simplex virus 1 glycoprotein D-derived “asymptomatic” human CD8+ T-cell epitopes decreases spontaneous ocular shedding in latently infected HLA transgenic rabbits: association with low frequency of local PD-1+ TIM-3+ CD8+ exhausted T cells.
    Khan AA; Srivastava R; Chentoufi AA; Geertsema R; Thai NT; Dasgupta G; Osorio N; Kalantari M; Nesburn AB; Wechsler SL; BenMohamed L
    J Virol; 2015 Jul; 89(13):6619-32. PubMed ID: 25878105
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reduced immune responses after vaccination with a recombinant herpes simplex virus type 1 vector in the presence of antiviral immunity.
    Lauterbach H; Ried C; Epstein AL; Marconi P; Brocker T
    J Gen Virol; 2005 Sep; 86(Pt 9):2401-2410. PubMed ID: 16099897
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Tat protein broadens T cell responses directed to the HIV-1 antigens Gag and Env: implications for the design of new vaccination strategies against AIDS.
    Gavioli R; Cellini S; Castaldello A; Voltan R; Gallerani E; Gagliardoni F; Fortini C; Cofano EB; Triulzi C; Cafaro A; Srivastava I; Barnett S; Caputo A; Ensoli B
    Vaccine; 2008 Jan; 26(5):727-37. PubMed ID: 18096278
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunogenicity of herpes simplex virus type 1 mutants containing deletions in one or more alpha-genes: ICP4, ICP27, ICP22, and ICP0.
    Brehm M; Samaniego LA; Bonneau RH; DeLuca NA; Tevethia SS
    Virology; 1999 Apr; 256(2):258-69. PubMed ID: 10191191
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Randomized, Double-Blinded, Placebo-Controlled, Phase 1 Study of a Replication-Defective Herpes Simplex Virus (HSV) Type 2 Vaccine, HSV529, in Adults With or Without HSV Infection.
    Dropulic LK; Oestreich MC; Pietz HL; Laing KJ; Hunsberger S; Lumbard K; Garabedian D; Turk SP; Chen A; Hornung RL; Seshadri C; Smith MT; Hosken NA; Phogat S; Chang LJ; Koelle DM; Wang K; Cohen JI
    J Infect Dis; 2019 Aug; 220(6):990-1000. PubMed ID: 31058977
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A single intramuscular vaccination of mice with the HSV-1 VC2 virus with mutations in the glycoprotein K and the membrane protein UL20 confers full protection against lethal intravaginal challenge with virulent HSV-1 and HSV-2 strains.
    Stanfield BA; Stahl J; Chouljenko VN; Subramanian R; Charles AS; Saied AA; Walker JD; Kousoulas KG
    PLoS One; 2014; 9(10):e109890. PubMed ID: 25350288
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Attenuated Herpes Simplex Virus 1 (HSV-1) Expressing a Mutant Form of ICP6 Stimulates a Strong Immune Response That Protects Mice against HSV-1-Induced Corneal Disease.
    Davido DJ; Tu EM; Wang H; Korom M; Gazquez Casals A; Reddy PJ; Mostafa HH; Combs B; Haenchen SD; Morrison LA
    J Virol; 2018 Sep; 92(17):. PubMed ID: 29950407
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Protective immunity against lethal HSV-1 challenge in mice by nucleic acid-based immunisation with herpes simplex virus type-1 genes specifying glycoproteins gB and gD.
    Baghian A; Chouljenko VN; D'Auvergne O; Newman MJ; Baghian S; Kousoulas KG
    J Med Microbiol; 2002 Apr; 51(4):350-357. PubMed ID: 11926742
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunization with HSV-1 glycoprotein C prevents immune evasion from complement and enhances the efficacy of an HSV-1 glycoprotein D subunit vaccine.
    Awasthi S; Lubinski JM; Friedman HM
    Vaccine; 2009 Nov; 27(49):6845-53. PubMed ID: 19761834
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of adjuvant efficacy of herpes simplex virus type 1 recombinant viruses expressing TH1 and TH2 cytokine genes.
    Osorio Y; Ghiasi H
    J Virol; 2003 May; 77(10):5774-83. PubMed ID: 12719570
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of novel immunodominant CD4+ Th1-type T-cell peptide epitopes from herpes simplex virus glycoprotein D that confer protective immunity.
    BenMohamed L; Bertrand G; McNamara CD; Gras-Masse H; Hammer J; Wechsler SL; Nesburn AB
    J Virol; 2003 Sep; 77(17):9463-73. PubMed ID: 12915561
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Protective immunity to genital herpes simplex virus type 1 and type 2 provided by self-adjuvanting lipopeptides that drive dendritic cell maturation and elicit a polarized Th1 immune response.
    Bettahi I; Zhang X; Afifi RE; BenMohamed L
    Viral Immunol; 2006; 19(2):220-36. PubMed ID: 16817765
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A L.E.A.P.S. heteroconjugate vaccine containing a T cell epitope from HSV-1 glycoprotein D elicits Th1 responses and protection.
    Goel N; Rong Q; Zimmerman D; Rosenthal KS
    Vaccine; 2003 Oct; 21(27-30):4410-20. PubMed ID: 14505924
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A HSV1 mutant leads to an attenuated phenotype and induces immunity with a protective effect.
    Xu X; Feng X; Wang L; Yi T; Zheng L; Jiang G; Fan S; Liao Y; Feng M; Zhang Y; Li D; Li Q
    PLoS Pathog; 2020 Aug; 16(8):e1008703. PubMed ID: 32776994
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.